Jan 11, 2019

Former CEO of Insys to Plead Guilty in Opioid-Kickback Scheme

By |January 11th, 2019|Dangerous Drugs|

In late December of 2018, federal prosecutors announced that Michael Babich, former CEO of Insys Therapeutics, agreed to plead guilty to participating in a bribery scheme which gave kickbacks to doctors in exchange for prescribing a powerful opioid painkiller. Babich, who resigned his role as CEO of the Arizona-based drug manufacturing firm, was scheduled to face trial next month; he has agreed to plead guilty to conspiracy and mail fraud charges, according to [...]

Sep 18, 2018

Januvia and Byetta Lawsuits Are Going Back to Court

By |September 18th, 2018|Dangerous Drugs|

Januvia and Byetta, along with Janumet and Victoza, are the diabetes drugs at the center of 945 lawsuits. The cases had originally been dismissed, but a federal appeals court overturned that decision in December of 2017, and remanded the cases back to U.S. District Judge Anthony Battaglia in the Southern District of California. He has ordered that the first bellwether cases must be selected by December 14, 2018, which means the courts could [...]

Jun 27, 2018

Opioid Antidote Naloxone Recalled by Manufacturer

By |June 27th, 2018|Dangerous Drugs|

Drug manufacturer Hospira has recalled Naloxone, the medication commonly used by first responders, medical professionals, and hospitals to quickly reverse suspected conditions of an opioid overdose. The National Institute on Drug Abuse states that Naloxone works as an opioid antagonist, attaching to opioid receptors in the brain. Therefore, when it is administered to a drug overdose victim, it works quickly to recover respiration when breathing has slowed down or ceased completely from the [...]

Jun 20, 2018

Voluntary Withdrawal of Zinbryta from the Market After Concerns Arise Over Liver and Brain Damage

By |June 20th, 2018|Dangerous Drugs|

The drug Zinbryta has been recalled on a voluntary basis by its manufacturers according to the recommendation of the European Medicines Agency (EMA) in cooperation with the Food & Drug Administration (FDA). Zinbryta (daclizumab) was approved by the FDA in May 2016 for the treatment of individuals suffering from various relapses of multiple sclerosis (MS). The use of the drug has been limited to approximately 8000 patients with MS in the wake of [...]

Jun 14, 2018

Ocaliva Dosage Errors Prompt the FDA to Require New Black Box Warning

By |June 14th, 2018|Dangerous Drugs|

FDA officials have now added a boxed warning label to obeticholic acid (Ocaliva), a liver disease medicine, in order to emphasize the proper dosing patients with rare chronic liver disease should follow. The FDA announcement states that the designated daily dosage for obeticholic acid, manufactured by Intercept Pharmaceuticals, has been incorrect. Instead, the dosage has been changed to weekly for patients suffering from moderate to severe primary biliary cholangitis (PBC). The former daily [...]

Jun 12, 2018

Nuplazid Produced Worsening Conditions for Many Users

By |June 12th, 2018|Dangerous Drugs|

Anti-psychotic drug Nuplazid (pimavanserin) is manufactured by Acadia pharmaceuticals and approved by the Federal Drug Administration (FDA) for treating Parkinson’s disease patients with debilitating psychosis. The process of approval used for Nuplazid allowed an expedited pharmaceutical safety review by categorizing this drug as a breakthrough therapy. Instituted by Congress in 2012, this breakthrough therapy classification was intended to expedite the FDA’s approval process for drugs that, based on evidence, could substantially improve the [...]

Jun 4, 2018

Warning: These Teething Medicines Are Unsafe for Your Baby

By |June 4th, 2018|Dangerous Drugs|

The U.S. Food and Drug Administration (FDA) is warning consumers about an over-the-counter teething medication for infants and children under the age of two that could be harmful. The agency says that products containing benzocaine are dangerous and pose a serious risk to infants and children under two. Benzocaine is used to treat sore gums, sore throats, and mouth irritation in children and infants. It can be found in brands like Orajel, Baby [...]

May 24, 2018

Several Diabetes Drugs May Cause Increased Risk of Toe Amputation

By |May 24th, 2018|Dangerous Drugs|

Recent findings provided by the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) detail the connection between the use of several diabetes drugs and the elevated risk of toe amputation. The diabetes drugs that pose this serious risk to patients are classified as sodium-glucose cotransporter-2 (SGLT2) inhibitors used to treat individuals with Type 2 diabetes. Active ingredients in these drugs include canagliflozin, empagliflozin, and dapagliflozin. Invokana and Invokamet, plus others [...]

May 15, 2018

Man Loses His Lower Right Leg After Using Invokana Diabetes Drug

By |May 15th, 2018|Dangerous Drugs|

Michael R. Wilkinson was prescribed Invokana (otherwise referred to as canagliflozin) in order to help manage his diabetic condition. He began taking the drug in April 2015. By December that same year, he was forced to undergo an amputation of his right leg below the knee. Unaware of the possible connection between his use of Invokana and the resulting amputation, Wilkinson continued to take the drug until May 2017. Wilkinson was only prompted [...]

May 3, 2018

Concerns about Invokana and Lower Limb Amputation Risks

By |May 3rd, 2018|Dangerous Drugs|

The drug Invokana, also referred to as canagliflozin, is used to treat patients for Type 2 diabetes. Invokana first entered the market in 2013. Since then it has become one of the most widely used diabetes medications in the U.S. Alarmingly, the drug has been linked to a number of difference serious side effects and health risks, including the risk of limb loss. Despite the knowledge of these dangerous side effects and health [...]

National Trial Lawyers
South Carolina Association for Justice
Super Lawyers

Free Case Evaluation

No-Obligation Case Review:

  • How do you prefer that we contact you? *
Text Us888-302-7546